Effect of dominant negative transforming growth factor-β receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line

Cancer Research

Volumn 67, Issue 14, 2007, Pages 6717-6724

  Geun, Taek Lee ^a   Jun, Hyuk Hong ^a,b   Kwak, Cheol ^c   Woo, Jaesung ^c   Liu, Victoria ^d   Lee, Chung ^c,d   Kim, Isaac Yi ^a,c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME BLOOD LEVEL; GENE CONSTRUCT; GENE OVEREXPRESSION; KIDNEY CARCINOMA; MACROPHAGE ACTIVATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR GENE; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENES, DOMINANT; HUMANS; INTERFERON TYPE II; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547132326     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4263     Document Type: Article

References (43)

1. Kale VP, Vaidya AA. Molecular mechanisms behind the dose-dependent differential activation of MAPK pathways induced by transforming growth factor-β1 in hematopoietic cells. Stem Cells Dev 2004;13:536-47.
2. Zhou W, Park I, Pins M, et al. Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1. Endocrinology 2003; 144:4280-4.
3. Mentlein R, Held-Feindt J. Angiogenesis factors in gliomas: a new key to tumour therapy? Naturwissenschaften 2003;90:385-94.
4. Cheng T, Shen H, Rodrigues N, Stier S, Scadden DT. Transforming growth factor β1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21(Cip1/Waf1) or p27(Kip1). Blood 2001;98:3643-9.
5. Pollman MJ, Naumovski L, Gibbons GH. Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-β1 in endothelial cells versus smooth muscle cells. Circulation 1999;99:2019-26.
6. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol 1998;16:137-61.
7. Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993;90:770-4.
8. Shah AH, Tabayoyong WB, Kundu SD, et al. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res 2002;62:7135-8.
9. Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C. Reconstitution of lethally irradiated adult mice with dominant negative TGF-β type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 2002; 169:3485-91.
10. Ruco LP, Meltzer MS. Macrophage activation for tumor cytotoxicity: tumoricidal activity by macrophages from C3H/HeJ mice requires at least two activation stimuli. Cell Immunol 1978;41:35-51.
11. Henson PM, Riches DW. Modulation of macrophage maturation by cytokines and lipid mediators: a potential role in resolution of pulmonary inflammation. Ann N Y Acad Sci 1994;725:298-308.
12. Yang N, Wu LL, Nikolic-Paterson DJ, et al. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 1998;13:1967-74.
13. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-β1 -β2 and -β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol 1990;145:940-4.
14. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988;334:260-2.
15. McCartney-Francis NL, Wahl SM. Dysregulation of IFN-γ signaling pathways in the absence of TGF-β1. J Immunol 2002;169:5941-7.
16. Seledtsova GV, Seledtsov VI, Taraban VY, Samarin DM, Kozlov VA. A role for interferon-γ and transforming growth factor-β in erythroid cell-mediated regulation of nitric oxide production in macrophages. Immunology 1997;91:109-13.
17. Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184-95.
18. Lin JY, Seguin R, Keller K, Chadee K. Transforming growth factor-β 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology 1995;85:400-7.
19. Chin BY, Petrache I, Choi AM, Choi ME. Transforming growth factor β1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 1999;274:11362-8.
20. Seyler I, Appel M, Devissaguet JP, Legrand P, Barratt G. Modulation of nitric oxide production in RAW 264.7 cells by transforming growth factor-β and interleukin-10: differential effects on free and encapsulated immunomodulator. J Leukoc Biol 1997;62:374-80.
21. Yan T, Riggs BL, Boyle WJ, Khosla S. Regulation of osteoclastogenesis and RANK expression by TGF-β1. J Cell Biochem 2001;83:320-5.
22. Yaswen L, Kulkarni AB, Fredrickson T, et al. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 1996;87:1439-45.
23. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987;84:5788-92.
24. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann N Y Acad Sci 1993;685: 713-39.
25. Lee SM, Yune TY, Kim SJ, et al. Minocycline inhibits apoptotic cell death via attenuation of TNF-α expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures. J Neurochem 2004;91:568-78.
26. Sun W, Tadmori I, Yang L, Delgado M, Ganea D. Vasoactive intestinal peptide (VIP) inhibits TGF-β1 production in murine macrophages. J Neuroimmunol 2000;107:88-99.
27. Hausmann EH, Hao SY, Pace JL, Parmely M J. Transforming growth factor β1 and γ interferon provide opposing signals to lipopolysaccharide- activated mouse macrophages. Infect Immun 1994;62:3625-32.
28. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196: 254-65.
29. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000;17:445-51.
30. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000;60:5857-61.
31. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104:2224-34.
32. Conti P, DiGioacchino M. MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 2001;22:133-7.
33. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002;44:143-61.
34. Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990;50:7450-6.
35. Eymard JC, Lopez M, Cattan A, Bouche O, Adjizian JC, Bernard J. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur J Cancer 1996;32A:1905-11.
36. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
37. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993;342:148-9.
38. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
39. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000;6:3545-51.
40. Lewis JS, Landers RJ, Underwood JC, Harris AL, Lewis CE. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000;192:150-8.
41. Hildenbrand R, Wolf G, Bohme B, Bleyl U, Steinborn A. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999;66: 40-9.
42. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-22.
43. + T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005;65:1761-9.